ArticleISME communications2021
Genetically modifying skin microbe to produce violacein and augmenting microbiome did not defend Panamanian golden frogs from disease.
Article in ISME communications, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 26 citations in OpenAlex.
- Review
- The Emergence of a CRISPR-Cas Revolution in Ecology: Applications, Challenges, and an Ecologist's Overview of the Toolbox.Molecular ecology resources · 2026Review
- Identification of Opportunistic Pathogens on the Skin of Salamanders for Use as Molecular Targets of a De Novo Design of Multitarget Anti-International journal of microbiology · 2026Article
- Novel antimicrobial peptides and peptide-microbiome crosstalk in Appalachian salamander skin.NPJ biofilms and microbiomes · 2025Article
- Probiotic colonization ofInfection and immunity · 2025Article
- Amphibian skin bacteria contain a wide repertoire of genes linked to their antifungal capacities.World journal of microbiology & biotechnology · 2025Article
- Identification and characterization ofMicrobiology spectrum · 2025Article
- Skin microbiomes of frogs vary among body regions, revealing differences that reflect known patterns of chytrid infection.Frontiers in microbiology · 2025Article
- The impact of microbiome diversity and composition on host health and susceptibility to disease across amphibian life stages.Frontiers in amphibian and reptile science · 2025Article
- Priority effects alter microbiome composition and increase abundance of probiotic taxa in treefrog tadpoles.Applied and environmental microbiology · 2024Article
- Phylosymbiosis shapes skin bacterial communities and pathogen-protective function in Appalachian salamanders.The ISME journal · 2024Article
- Molecular detection ofPeerJ · 2024Article
- Mr. Toad's Wild Fungi: Fungal Isolate Diversity on Colorado Boreal Toads and their Capacity for Pathogen Inhibition.Fungal ecology · 2023Article
- When Defenses Fail: Atelopus zeteki Skin Secretions Increase Growth of the Pathogen Batrachochytrium dendrobatidis.Integrative and comparative biology · 2022Article
- A Framework for the Systematic Selection of Biosensor Chassis for Environmental Synthetic Biology.ACS synthetic biology · 2022Review
- Parallel engineering of environmental bacteria and performance over years under jungle-simulated conditions.PloS one · 2022Article
Corrections and comments
- Erratum issued
Authors and funding
14 authors at 3 institutions in 1 country.
Funding
Abstract
We designed two probiotic treatments to control chytridiomycosis caused by Batrachochytrium dendrobatidis (Bd) on infected Panamanian golden frogs (Atelopus zeteki), a species that is thought to be extinct in the wild due to Bd. The first approach disrupted the existing skin microbe community with antibiotics then exposed the frogs to a core golden frog skin microbe (Diaphorobacter sp.) that we genetically modified to produce high titers of violacein, a known antifungal compound. One day following probiotic treatment, the engineered Diaphorobacter and the violacein-producing pathway could be detected on the frogs but the treatment failed to improve frog survival when exposed to Bd. The second approach exposed frogs to the genetically modified bacterium mixed into a consortium with six other known anti-Bd bacteria isolated from captive A. zeteki, with no preliminary antibiotic treatment. The consortium treatment increased the frequency and abundance of three probiotic isolates (Janthinobacterium, Chryseobacterium, and Stenotrophomonas) and these persisted on the skin 4 weeks after probiotic treatment. There was a temporary increase in the frequency and abundance of three other probiotics isolates (Masillia, Serratia, and Pseudomonas) and the engineered Diaphorobacter isolate, but they subsequently disappeared from the skin. This treatment also failed to reduce frog mortality upon exposure.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.